Contineum Therapeutics (CTNM) Q3 2026 earnings summary

Executive summary

• PIPE-791 is the lead wholly owned candidate; PROPEL-IPF patient dosing began in Q1 2026, with trial completion targeted for June 2028.

• J&J’s Phase 2 MOONLIGHT-1 trial of PIPE-307 in major depressive disorder missed its primary endpoint; it was well tolerated, and J&J is reviewing exploratory data before deciding next steps.

• Cash, cash equivalents and marketable securities totaled $244.5 million at September 30, 2026; management projects funding for planned operations through mid-2029.

Financial highlights

• Q3 2026 operating expenses were $21.0 million versus $14.9 million YoY; net loss was $18.7 million versus $12.8 million.

• Q3 R&D expense was $16.0 million, up 45% YoY, primarily from PIPE-791 development and employee-related costs; G&A was $5.0 million, up 26%, mainly from stock compensation and employee costs.

• 9M 2026 operating expenses were $55.3 million versus $50.9 million; net loss was $48.3 million versus $44.8 million.

• 9M R&D expense was $40.3 million versus $38.8 million; G&A was $15.0 million versus $12.2 million, with higher stock compensation and personnel costs contributing to the increase.

• No revenue was recognized in Q3 or 9M 2026; interest income was $2.4 million for Q3 and $7.2 million for 9M.

Outlook and guidance

• Management expects available cash resources to fund planned operations through mid-2029, one year beyond the estimated completion of the IPF trial.

• PROPEL-IPF evaluates once-daily oral PIPE-791 over 26 weeks in approximately 324 IPF patients; completion remains targeted for June 2028.

• Operating expenses, particularly R&D, are expected to increase substantially as clinical development, pipeline work, headcount and public-company activities continue.

• Future funding may come from equity, debt or commercial arrangements; financing may be unavailable or require dilution or concessions on program rights.